Patents by Inventor Sela Cheifetz

Sela Cheifetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant production of soluble TGF-.beta.-binding endoglin polypeptides
    Patent number: 6015693
    Abstract: This invention provides a novel purified TGF-.beta.-binding glycoprotein, endoglin, an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to the TGF-.beta.-binding glycoprotein, soluble endoglin-derived polypeptide, and fragments thereof. A pharmaceutical composition which comprises the endoglin-derived polypeptide purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: January 18, 2000
    Assignee: Telios Pharmaceuticals, Inc.
    Inventors: Michelle Letarte, Joan Massague, Carmelo Bernabeu, Sela Cheifetz
  • Soluble TGF-.beta.-binding endoglin polypeptides and homodimers
    Patent number: 5830847
    Abstract: This invention provides a novel purified TGF-.beta.-binding glycoprotein, endoglin, an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to the TGF-.beta.-binding glycoprotein, soluble endoglin-derived polypeptide, and fragments thereof. A pharmaceutical composition which comprises the endoglin-derived polypeptide purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.
    Type: Grant
    Filed: October 30, 1992
    Date of Patent: November 3, 1998
    Assignee: HSC Research & Development Limited Partnership
    Inventors: Michelle Letarte, Joan Massague, Carmelo Bernabeu, Sela Cheifetz
  • Use of endoglin polypeptides for modifying the regulatory activity of TGF-.beta.
    Patent number: 5719120
    Abstract: This invention provides a novel purified TGF-.beta.-binding glycoprotein, endoglin, an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to the TGF-.beta.-binding glycoprotein, soluble endoglin-derived polypeptide, and fragments thereof. A pharmaceutical composition which comprises the endoglin-derived polypeptide purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 17, 1998
    Assignee: HSC Research & Development Limited Partnership
    Inventors: Michelle Letarte, Joan Massague, Carmelo Bernabeu, Sela Cheifetz